WaveMan · Form 4
Dier Mardi insider trades
> Search tickers & screens ⌘K
LIVE

Dier Mardi insider trades

Dier Mardi has filed 22 Form 4s with the SEC that we hold, for Madrigal Pharmaceuticals, INC. (MDGL) (EVP and CFO), Oric Pharmaceuticals, Inc. (ORIC) (Director), Ultragenyx Pharmaceutical Inc. (RARE) (CFO & Executive Vice President) and Prelude Therapeutics Inc (PRLD) (Director), among 5 companies in all. Across all of them we count 2 purchases worth $115.8K and 37 sales worth $5.3M reported on Form 4. In the last 12 months: 0 purchases ($0) and 28 sales ($3.8M). The largest single trade was a sale of 1,183 shares of Madrigal Pharmaceuticals, INC. worth $505.4K, dated 2026-03-02. The first filing on our record is dated 2021-10-14 and the latest 2026-03-06.

Madrigal Pharmaceuticals, INC. (MDGL)

EVP and CFO · 6 filings · 31 purchases and sales
Trade dateCodeSharesValue as filedFiled
2025-03-03S, sale reported on Form 41,187$386.8K2025-03-05
2025-03-03S, sale reported on Form 4774$250.4K2025-03-05
2025-03-10S, sale reported on Form 4258$83.3K2025-03-12
2025-12-02S, sale reported on Form 4717$411.6K2025-12-03
2025-12-02S, sale reported on Form 480$47.7K2025-12-03
2025-12-02S, sale reported on Form 474$44.0K2025-12-03
2025-12-02S, sale reported on Form 4160$94.5K2025-12-03
2025-12-02S, sale reported on Form 4160$94.3K2025-12-03
2025-12-02S, sale reported on Form 4240$141.1K2025-12-03
2025-12-02S, sale reported on Form 4240$140.5K2025-12-03
2025-12-02S, sale reported on Form 4480$278.3K2025-12-03
2025-12-02S, sale reported on Form 4258$149.3K2025-12-03
2025-12-02S, sale reported on Form 4320$184.9K2025-12-03
2025-12-02S, sale reported on Form 4240$138.3K2025-12-03
2025-12-02S, sale reported on Form 4320$182.5K2025-12-03
2025-12-02S, sale reported on Form 4410$234.5K2025-12-03
2025-12-02S, sale reported on Form 4354$202.8K2025-12-03
2025-12-02S, sale reported on Form 4120$69.0K2025-12-03
2026-03-02S, sale reported on Form 41,183$505.4K2026-03-02
2026-03-06S, sale reported on Form 4160$69.5K2026-03-06
2026-03-06S, sale reported on Form 480$34.8K2026-03-06
2026-03-06S, sale reported on Form 480$34.9K2026-03-06
2026-03-06S, sale reported on Form 440$17.5K2026-03-06
2026-03-06S, sale reported on Form 4646$279.0K2026-03-06
2026-03-06S, sale reported on Form 440$17.0K2026-03-06
2026-03-06S, sale reported on Form 4420$179.3K2026-03-06
2026-03-06S, sale reported on Form 480$34.2K2026-03-06
2026-03-06S, sale reported on Form 4160$68.6K2026-03-06
2026-03-06S, sale reported on Form 440$17.2K2026-03-06
2026-03-06S, sale reported on Form 4120$51.7K2026-03-06
2026-03-06S, sale reported on Form 4116$50.2K2026-03-06

Oric Pharmaceuticals, Inc. (ORIC)

Director · 5 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Ultragenyx Pharmaceutical Inc. (RARE)

CFO & Executive Vice President · 5 filings · 6 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-10-12S, sale reported on Form 43,477$287.9K2021-10-14
2021-10-14S, sale reported on Form 43,261$264.7K2021-10-14
2022-03-01S, sale reported on Form 4534$35.6K2022-03-03
2022-03-03S, sale reported on Form 4420$27.1K2022-03-03
2022-10-12S, sale reported on Form 43,484$133.2K2022-10-14
2022-10-14S, sale reported on Form 41,629$65.4K2022-10-17

Prelude Therapeutics Inc (PRLD)

Director · 4 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

SLRN

CFO and CBO · 2 filings · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-05-09P, purchase reported on Form 45,556$100.0K2023-05-11
2023-05-09P, purchase reported on Form 4875$15.8K2023-05-11
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1574591) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms